Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Powering Up In Emerging Markets Through Alliance And Pricing Strategies

This article was originally published in PharmAsia News

Executive Summary

As Merck looks to expand its geographic footprint in emerging markets, local players with extensive distribution networks will be the focus for partnerships, Merck Chief Strategy Officer and former Emerging Markets R&D Head Mervyn Turner told investors at the CLSA Emerging Markets Pharma Conference Dec.1 in New York

You may also be interested in...



Tender, Tender On The Wall, What Lies Ahead For China In 2013?

The Chinese New Year is just around the corner, and many provinces are gearing up to initiate drug and high-end medical device tenders, leaving plenty for pharma and device executives to consider heading into 2013.

Will World's Largest HCV Population Have Access To Newest Treatments?

With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources

Will World's Largest HCV Population Have Access To Newest Treatments?

With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources

Related Content

Latest News
UsernamePublicRestriction

Register

SC073941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel